Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs (1994)

Peer-Reviewed Study · Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, et al. · May 1994

Schinkel AH et al., 1994-05: Mouse knockout study establishing that P-glycoprotein (mdr1a) at the blood-brain barrier keeps ivermectin out of the brain; mice lacking it were about 100-fold more sensitive to ivermectin. It is the founding document for the blood-brain-barrier account of ivermectin neurotoxicity.

they displayed an increased sensitivity to the centrally neurotoxic pesticide ivermectin (100-fold) and to the carcinostatic drug vinblastine (3-fold)

Schinkel AH et al., 1994-05: Mouse knockout study establishing that P-glycoprotein (mdr1a) at the blood-brain barrier keeps ivermectin out of the brain; mice lacking it were about 100-fold more sensitive to ivermectin. It is the founding document for the blood-brain-barrier account of ivermectin neurotoxicity. C4 mechanism. Study type: animal (gene-knockout mouse) study; N not stated in the abstract; Netherlands (Netherlands Cancer Institute). Dose/route: ivermectin challenge in mdr1a (-/-) vs (+/+) mice, route not stated in the abstract. Comparator: wild-type mdr1a (+/+) mice. Funder and declared conflicts: not in the PubMed record. The paper's own conclusion is that 'the mdr1a P-glycoprotein is the major P-glycoprotein in the blood-brain barrier and that its absence results in elevated drug levels in many tissues (especially in brain)'. Also filed as IVA-43 (claims C4, C9). Study type: animal.